📊 UPB Key Takeaways
Is Upstream Bio, Inc. (UPB) a Good Investment?
Upstream Bio is a development-stage pharmaceutical company with a fortress balance sheet ($96.7M cash, minimal debt) providing downside protection, but severe operating losses ($43.6M) against minimal revenue ($1.0M) create existential burn risk. With annual negative cash flow of $48M, the company has approximately 2 years of runway to achieve clinical or commercial milestones before requiring capital raises.
Upstream Bio, Inc. Key Strengths (UPB)
- Strong balance sheet with $96.7M cash reserves and only $14.1M total liabilities
- Zero long-term debt eliminates financial distress risk in near term
- Exceptional liquidity position (23.14x current ratio) supports extended operations
- Revenue growth of 20.4% YoY indicates emerging commercial traction despite early stage
UPB Stock Risks: Upstream Bio, Inc. Investment Risks
- Operating losses of $43.6M against $1.0M revenue indicates severe unprofitability and pre-revenue stage
- Negative free cash flow of $48M annually with only $96.7M runway (~2 years at current burn)
- Pharmaceutical development carries high clinical, regulatory, and execution risk with uncertain outcomes
- Heavy R&D burn model typical of biotech requires successful commercialization or significant capital raises
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Clinical trial advancement, regulatory approvals, and drug development pipeline milestones
- Revenue growth rate from product commercialization or licensing revenues
Upstream Bio, Inc. (UPB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 23.14x current ratio provides a solid financial cushion.
UPB Profit Margin, ROE & Profitability Analysis
UPB vs Healthcare Sector: How Upstream Bio, Inc. Compares
How Upstream Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Upstream Bio, Inc. Stock Overvalued? UPB Valuation Analysis 2026
Based on fundamental analysis, Upstream Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Upstream Bio, Inc. Balance Sheet: UPB Debt, Cash & Liquidity
UPB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Upstream Bio, Inc.'s revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.58 indicates the company is currently unprofitable.
UPB Revenue Growth, EPS Growth & YoY Performance
UPB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $566.0K | -$27.3M | $-0.51 |
| Q3 2025 | $607.0K | -$10.9M | $-0.63 |
| Q2 2025 | $510.0K | -$10.9M | $-0.74 |
| Q1 2025 | $566.0K | -$10.9M | $-0.51 |
| Q3 2024 | $607.0K | -$2.5M | $-2.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Upstream Bio, Inc. Dividends, Buybacks & Capital Allocation
UPB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Upstream Bio, Inc. (CIK: 0002022626)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UPB
What is the AI rating for UPB?
Upstream Bio, Inc. (UPB) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UPB's key strengths?
Claude: Strong balance sheet with $96.7M cash reserves and only $14.1M total liabilities. Zero long-term debt eliminates financial distress risk in near term.
What are the risks of investing in UPB?
Claude: Operating losses of $43.6M against $1.0M revenue indicates severe unprofitability and pre-revenue stage. Negative free cash flow of $48M annually with only $96.7M runway (~2 years at current burn).
What is UPB's revenue and growth?
Upstream Bio, Inc. reported revenue of $1.0M.
Does UPB pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
Where can I find UPB SEC filings?
Official SEC filings for Upstream Bio, Inc. (CIK: 0002022626) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UPB's EPS?
Upstream Bio, Inc. has a diluted EPS of $-0.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is UPB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Upstream Bio, Inc. has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is UPB stock overvalued or undervalued?
Valuation metrics for UPB: ROE of -13.4% (sector avg: 15%), net margin of -3,925.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is UPB's AI grade for 2026?
Our dual AI analysis gives Upstream Bio, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is UPB's free cash flow?
Upstream Bio, Inc.'s operating cash flow is $-47.9M, with capital expenditures of $165.0K. FCF margin is -4,643.8%.
How does UPB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,925.6% (avg: 12%), ROE -13.4% (avg: 15%), current ratio 23.14 (avg: 2).